Journey Medical Corp Financials

DERM

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Journey Medical Corp (DERM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 20/100

Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Journey Medical Corp has an operating margin of -24.4%, meaning the company retains $-24 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -2.6% the prior year.

Growth

Journey Medical Corp's revenue declined 29.1% year-over-year, from $79.2M to $56.1M. This contraction results in a growth score of 0/100.

Leverage

Journey Medical Corp carries a low D/E ratio of 1.24, meaning only $1.24 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 65/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Journey Medical Corp's current ratio of 1.37 indicates adequate short-term liquidity, earning a score of 35/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

While Journey Medical Corp generated -$9.1M in operating cash flow, capex of $15.0M consumed most of it, leaving -$24.1M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Piotroski F-Score Weak

2/9

Journey Medical Corp passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Low Quality

0.62x

For every $1 of reported earnings, Journey Medical Corp generates $0.62 in operating cash flow (-$9.1M OCF vs -$14.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-5.1x

Journey Medical Corp earns $-5.1 in operating income for every $1 of interest expense (-$13.7M vs $2.7M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Revenue

$56.1M

YoY-29.1%

Journey Medical Corp generated $56.1M in revenue in fiscal year 2024. This represents a decrease of 29.1% from the prior year.

EBITDA

N/A

Free Cash Flow

-$24.1M

YoY-10152.9%

Journey Medical Corp generated -$24.1M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 10152.9% from the prior year.

Net Income

-$14.7M

YoY-280.8%

Journey Medical Corp reported -$14.7M in net income in fiscal year 2024. This represents a decrease of 280.8% from the prior year.

EPS (Diluted)

$-0.72

YoY-242.9%

Journey Medical Corp earned $-0.72 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 242.9% from the prior year.

Cash & Debt

$20.3M

YoY-26.0%

Journey Medical Corp held $20.3M in cash against $24.9M in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

N/A

Gross Margin

62.8%

YoY-8.3pp

Journey Medical Corp's gross margin was 62.8% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is down 8.3 percentage points from the prior year.

Operating Margin

-24.4%

YoY-21.7pp

Journey Medical Corp's operating margin was -24.4% in fiscal year 2024, reflecting core business profitability. This is down 21.7 percentage points from the prior year.

Net Margin

-26.1%

YoY-21.3pp

Journey Medical Corp's net profit margin was -26.1% in fiscal year 2024, showing the share of revenue converted to profit. This is down 21.3 percentage points from the prior year.

Return on Equity

N/A

R&D Spending

$9.9M

YoY+30.7%

Journey Medical Corp invested $9.9M in research and development in fiscal year 2024. This represents an increase of 30.7% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$15.0M

YoY+200.0%

Journey Medical Corp invested $15.0M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 200.0% from the prior year.

DERM Income Statement

Metric	FY24	FY23	FY22	FY21	FY20
Revenue	$56.1M-29.1%	$79.2M+7.5%	$73.7M+16.7%	$63.1M+41.8%	$44.5M
Cost of Revenue	$20.9M-8.8%	$22.9M-25.6%	$30.8M-4.1%	$32.1M+119.8%	$14.6M
Gross Profit	$35.3M-37.4%	$56.3M+31.2%	$42.9M+38.1%	$31.1M+3.7%	$29.9M
R&D Expenses	$9.9M+30.7%	$7.5M-31.1%	$10.9M+299.5%	$2.7M	N/A
SG&A Expenses	$40.2M-8.4%	$43.9M-26.2%	$59.5M+49.3%	$39.8M+80.4%	$22.1M
Operating Income	-$13.7M-559.8%	-$2.1M+92.5%	-$27.5M+21.1%	-$34.9M-544.3%	$7.9M
Interest Expense	$2.7M+59.0%	$1.7M-15.9%	$2.0M-71.3%	$7.0M+907.7%	$698K
Income Tax	$61K-72.4%	$221K+250.8%	$63K-96.1%	$1.6M-12.6%	$1.9M
Net Income	-$14.7M-280.8%	-$3.9M+87.0%	-$29.6M+32.7%	-$44.0M-932.7%	$5.3M
EPS (Diluted)	$-0.72-242.9%	$-0.21+87.6%	$-1.69+60.9%	$-4.32	$0.49

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Revenue	$17.6M+17.5%	$15.0M+14.2%	$13.1M-3.5%	$13.6M-8.3%	$14.9M+14.0%	$13.0M-14.6%	$15.3M-55.8%	$34.5M
Cost of Revenue	$5.8M+16.5%	$4.9M+3.1%	$4.8M+114.1%	$2.2M-65.8%	$6.5M-4.0%	$6.8M+203.2%	$2.2M-65.0%	$6.4M
Gross Profit	$11.9M+17.9%	$10.1M+20.6%	$8.3M-26.7%	$11.4M+36.9%	$8.3M+33.8%	$6.2M-52.2%	$13.0M-53.7%	$28.1M
R&D Expenses	$287K	N/A	$39K-82.1%	$218K-76.1%	$913K-88.4%	$7.9M+423.9%	$1.5M-32.5%	$2.2M
SG&A Expenses	$12.1M+1.4%	$11.9M+12.4%	$10.6M+5.1%	$10.1M-2.6%	$10.3M+22.7%	$8.4M-14.4%	$9.8M+14.0%	$8.6M
Operating Income	-$1.5M+46.8%	-$2.9M+13.5%	-$3.3M-248.8%	$2.2M+176.3%	-$2.9M+71.0%	-$10.1M-379.6%	-$2.1M-112.2%	$17.2M
Interest Expense	$814K+0.1%	$813K+3.0%	$789K-19.7%	$982K+96.8%	$499K-8.9%	$548K+2183.3%	$24K-91.0%	$268K
Income Tax	N/A	$60K	N/A	N/A	N/A	N/A	N/A	$95K
Net Income	-$2.3M+39.0%	-$3.8M+6.8%	-$4.1M-367.8%	$1.5M+145.3%	-$3.4M+67.8%	-$10.4M-387.3%	-$2.1M-112.8%	$16.8M
EPS (Diluted)	$-0.09+43.8%	$-0.16+11.1%	$-0.18-280.0%	$0.10+158.8%	$-0.17+67.9%	$-0.53-2750.0%	$0.02-97.5%	$0.80

DERM Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20
Total Assets	$80.2M+4.4%	$76.8M-26.9%	$105.2M+8.1%	$97.3M+87.4%	$51.9M
Current Assets	$48.2M-14.7%	$56.5M-27.3%	$77.7M-8.1%	$84.5M+139.8%	$35.2M
Cash & Equivalents	$20.3M-26.0%	$27.4M-14.3%	$32.0M-34.8%	$49.1M+495.2%	$8.2M
Inventory	$14.4M+41.4%	$10.2M-27.9%	$14.2M+43.6%	$9.9M+602.4%	$1.4M
Accounts Receivable	$10.2M-32.8%	$15.2M-46.0%	$28.2M+22.0%	$23.1M-3.4%	$23.9M
Goodwill	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$60.2M+6.5%	$56.5M-35.9%	$88.2M+59.6%	$55.2M+32.7%	$41.6M
Current Liabilities	$35.2M-16.0%	$41.9M-37.4%	$66.8M+29.5%	$51.6M+83.9%	$28.1M
Long-Term Debt	$24.9M+70.1%	$14.6M-26.2%	$19.8M	N/A	N/A
Total Equity	$20.1M-1.4%	$20.4M+19.8%	$17.0M-59.6%	$42.0M+308.5%	$10.3M
Retained Earnings	-$87.0M-20.3%	-$72.4M-5.6%	-$68.5M-76.2%	-$38.9M-859.3%	$5.1M

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Total Assets	$85.2M+5.0%	$81.2M-4.5%	$85.0M+5.9%	$80.2M+23.1%	$65.2M-2.1%	$66.6M-13.4%	$76.8M+16.6%	$65.9M
Current Assets	$56.4M+10.0%	$51.3M-5.0%	$54.0M+12.1%	$48.2M+3.7%	$46.5M-1.2%	$47.0M-16.7%	$56.5M+26.3%	$44.7M
Cash & Equivalents	$24.9M+22.9%	$20.3M-3.7%	$21.1M+3.8%	$20.3M-15.1%	$23.9M-0.6%	$24.1M-12.3%	$27.4M+10.9%	$24.7M
Inventory	$11.8M-8.0%	$12.9M+2.8%	$12.5M-13.4%	$14.4M+49.0%	$9.7M-8.4%	$10.6M+3.7%	$10.2M-7.4%	$11.0M
Accounts Receivable	$18.0M+15.0%	$15.6M-13.2%	$18.0M+76.2%	$10.2M-2.2%	$10.5M+6.8%	$9.8M-35.6%	$15.2M+90.5%	$8.0M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$59.3M-4.2%	$61.9M-2.4%	$63.4M+5.4%	$60.2M+11.6%	$53.9M+0.5%	$53.6M-5.1%	$56.5M+16.4%	$48.5M
Current Liabilities	$39.7M-1.9%	$40.5M+0.6%	$40.2M+14.3%	$35.2M+3.0%	$34.1M-12.3%	$38.9M-7.0%	$41.9M-13.7%	$48.5M
Long-Term Debt	$19.5M-8.6%	$21.4M-7.5%	$23.1M-7.1%	$24.9M+26.0%	$19.7M+34.5%	$14.7M+0.4%	$14.6M	$0
Total Equity	$25.9M+34.6%	$19.2M-10.7%	$21.5M+7.3%	$20.1M+77.7%	$11.3M-12.8%	$13.0M-36.4%	$20.4M+17.1%	$17.4M
Retained Earnings	-$97.2M-2.4%	-$94.9M-4.2%	-$91.1M-4.7%	-$87.0M-1.0%	-$86.2M-4.1%	-$82.8M-14.4%	-$72.4M-3.1%	-$70.2M

DERM Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$9.1M-274.2%	$5.2M+138.7%	-$13.5M-520.5%	-$2.2M-142.5%	$5.1M
Capital Expenditures	$15.0M+200.0%	$5.0M-75.0%	$20.0M	N/A	N/A
Free Cash Flow	-$24.1M-10152.9%	$240K+100.7%	-$33.5M	N/A	N/A
Investing Cash Flow	-$15.0M-200.0%	-$5.0M+75.0%	-$20.0M-100.0%	-$10.0M-733.3%	-$1.2M
Financing Cash Flow	$17.0M+453.7%	-$4.8M-129.2%	$16.5M-69.0%	$53.0M+10986.2%	-$487K
Dividends Paid	N/A	N/A	N/A	$820K	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Operating Cash Flow	-$2.4M-153.0%	-$942K+66.7%	-$2.8M-227.3%	$2.2M+143.0%	-$5.2M-3.1%	-$5.0M+69.6%	-$16.5M-188.1%	$18.7M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	-$16.5M-188.1%	$18.7M
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0
Financing Cash Flow	$7.0M+4165.5%	$165K-95.4%	$3.6M-66.1%	$10.6M+111.1%	$5.0M+207.3%	$1.6M-91.5%	$19.2M+275.0%	-$11.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

DERM Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20
Gross Margin	62.8%-8.3pp	71.1%+12.9pp	58.2%+9.1pp	49.2%-18.1pp	67.2%
Operating Margin	-24.4%-21.7pp	-2.6%+34.7pp	-37.4%+17.9pp	-55.3%-72.9pp	17.6%
Net Margin	-26.1%-21.3pp	-4.9%+35.4pp	-40.2%+29.5pp	-69.7%-81.5pp	11.9%
Return on Equity	N/A	N/A	N/A	N/A	51.3%
Return on Assets	-18.3%-13.3pp	-5.0%+23.2pp	-28.2%+17.0pp	-45.2%-55.4pp	10.2%
Current Ratio	1.37+0.0	1.35+0.2	1.16-0.5	1.64+0.4	1.26
Debt-to-Equity	1.24+0.5	0.72-0.4	1.17-0.1	1.31-2.7	4.04
FCF Margin	-43.0%-43.3pp	0.3%+45.8pp	-45.5%	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Gross Margin	67.4%+0.3pp	67.1%+3.6pp	63.5%-20.0pp	83.6%+27.6pp	56.0%+8.3pp	47.7%-37.6pp	85.3%+3.9pp	81.4%
Operating Margin	-8.7%+10.5pp	-19.2%+6.1pp	-25.3%-41.7pp	16.4%+36.1pp	-19.7%+57.7pp	-77.4%-63.6pp	-13.8%-63.7pp	49.9%
Net Margin	-13.1%+12.2pp	-25.3%+5.7pp	-31.0%-42.2pp	11.2%+33.8pp	-22.6%+57.5pp	-80.1%-66.1pp	-14.1%-62.7pp	48.6%
Return on Equity	N/A	N/A	N/A	7.6%	N/A	N/A	N/A	96.6%
Return on Assets	-2.7%+2.0pp	-4.7%+0.1pp	-4.8%-6.7pp	1.9%+7.1pp	-5.2%+10.5pp	-15.7%-12.9pp	-2.8%-28.3pp	25.5%
Current Ratio	1.42+0.2	1.27-0.1	1.34-0.0	1.370.0	1.36+0.2	1.21-0.1	1.35+0.4	0.92
Debt-to-Equity	0.75-0.4	1.11+0.0	1.07-0.2	1.24-0.5	1.75+0.6	1.13+0.4	0.72+0.7	0.00
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	-108.3%-162.6pp	54.3%

Similar Companies

China Sxt Pharmaceuticals Inc SXTC

$2.2M

Ironwood IRWD

$732.1M

Organigram Global Inc OGI

$174.3M

BioAge Labs Inc. BIOA

$817.1M

Citius Oncology, Inc. CTOR

$107.7M

Frequently Asked Questions

What is Journey Medical Corp's annual revenue?

Journey Medical Corp (DERM) reported $56.1M in total revenue for fiscal year 2024. This represents a -29.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Journey Medical Corp's revenue growing?

Journey Medical Corp (DERM) revenue declined by 29.1% year-over-year, from $79.2M to $56.1M in fiscal year 2024.

Is Journey Medical Corp profitable?

No, Journey Medical Corp (DERM) reported a net income of -$14.7M in fiscal year 2024, with a net profit margin of -26.1%.

What is Journey Medical Corp's earnings per share (EPS)?

Journey Medical Corp (DERM) reported diluted earnings per share of $-0.72 for fiscal year 2024. This represents a -242.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

How much debt does Journey Medical Corp have?

As of fiscal year 2024, Journey Medical Corp (DERM) had $20.3M in cash and equivalents against $24.9M in long-term debt.

What is Journey Medical Corp's gross margin?

Journey Medical Corp (DERM) had a gross margin of 62.8% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.

What is Journey Medical Corp's operating margin?

Journey Medical Corp (DERM) had an operating margin of -24.4% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Journey Medical Corp's net profit margin?

Journey Medical Corp (DERM) had a net profit margin of -26.1% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is Journey Medical Corp's free cash flow?

Journey Medical Corp (DERM) generated -$24.1M in free cash flow during fiscal year 2024. This represents a -10152.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Journey Medical Corp's operating cash flow?

Journey Medical Corp (DERM) generated -$9.1M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Journey Medical Corp's total assets?

Journey Medical Corp (DERM) had $80.2M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Journey Medical Corp's capital expenditures?

Journey Medical Corp (DERM) invested $15.0M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Journey Medical Corp spend on research and development?

Journey Medical Corp (DERM) invested $9.9M in research and development during fiscal year 2024.

What is Journey Medical Corp's current ratio?

Journey Medical Corp (DERM) had a current ratio of 1.37 as of fiscal year 2024, which is considered adequate.

What is Journey Medical Corp's debt-to-equity ratio?

Journey Medical Corp (DERM) had a debt-to-equity ratio of 1.24 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Journey Medical Corp's return on assets (ROA)?

Journey Medical Corp (DERM) had a return on assets of -18.3% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Journey Medical Corp's cash runway?

Based on fiscal year 2024 data, Journey Medical Corp (DERM) had $20.3M in cash against an annual operating cash burn of $9.1M. This gives an estimated cash runway of approximately 27 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Journey Medical Corp's Piotroski F-Score?

Journey Medical Corp (DERM) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Journey Medical Corp's earnings high quality?

Journey Medical Corp (DERM) has an earnings quality ratio of 0.62x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Journey Medical Corp cover its interest payments?

Journey Medical Corp (DERM) has an interest coverage ratio of -5.1x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Journey Medical Corp?

Journey Medical Corp (DERM) scores 20 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.